Haematological cancer: The rule of three in AML induction-is cladribine the answer?

Nature Reviews Clinical Oncology

Volumn 9, Issue 7, 2012, Pages 376-377

  Appelbaum, Frederick R ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLADRIBINE; CYTARABINE; DAUNORUBICIN; FLUDARABINE; GEMTUZUMAB OZOGAMICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW BIOPSY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; HEALTH CARE POLICY; HUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETREATMENT; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CLADRIBINE; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION;

EID: 84863435652     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2012.98     Document Type: Article

References (10)

1. th edn Ch. 104 (eds Abeloff, M. D. et al.) 2215-2234 (Elsevier, Philadelphia, USA, 2008).
2. Burnett, A. K. et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J. Clin. Oncol. 29, 369-377 (2011).
3. Holowiecki, J. et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2011.37.1286.
4. Holowiecki, J. et al. Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia 18, 989-997 (2004).
5. Fernandez, H. F. et al. Anthracycline dose intensification in acute myeloid leukemia. N. Engl. J. Med. 361, 1249-1259 (2009).
6. Petersdorf, S. et al. Preliminary results of Southwest Oncology Group Study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia [abstract]. Blood 114, a790 (2009).
7. Ohtake, S. et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 study. Blood 117, 2358-2365 (2011).
8. O'Donnell, M. R. et al. Acute myeloid leukemia. J. Natl Compr. Canc. Netw. 9, 280-317 (2011).
9. Luger, S. M. Is a nadir bone marrow required and, if so, what to do with residual disease? Best Pract. Res. Clin. Haematol. 24, 527-532 (2011).
10. Gandhi, V. et al. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmocodynamic, and molecular interactions. Blood 87, 256-264 (1996).